Vascular Solutions, Inc. (VASC) Reports In-Line Q2 EPS; Reaffirms
Tweet
Share
E-mailGet Alerts VASC Hot Sheet
Price: $56.00 --0%
Financial Fact:
General and administrative: 2.39M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Financial Fact:
General and administrative: 2.39M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Join SI Premium – FREE
Vascular Solutions, Inc. (NASDAQ: VASC) reported Q2 EPS of $0.17, in-line with the analyst estimate of $0.17. Revenue for the quarter came in at $27.4 million versus the consensus estimate of $27 million.
Vascular Solutions, Inc. sees FY2013 EPS of $0.66-$0.70, versus the consensus of $0.67. Vascular Solutions, Inc. sees FY2013 revenue of $107-110 million, versus the consensus of $107.7 million.
""Vascular Solutions reported another very strong quarter, with continued double-digit sales growth to a new record quarterly level combined with ongoing improvement in our operating margin," said Howard Root, Chief Executive Officer of Vascular Solutions. "We are especially pleased to achieve growth in all three of our product categories in light of the continuing challenges in the global healthcare environment. Our consistently strong financial performance reflects our demonstrated ability to develop and launch clinically-relevant new products on a continuing basis. With approximately ten new products scheduled for launch this year and 40 total new product ideas in our pipeline, we remain optimistic about our continued revenue and earnings growth for 2013 and beyond."
For earnings history and earnings-related data on Vascular Solutions, Inc. (VASC) click here.
Vascular Solutions, Inc. sees FY2013 EPS of $0.66-$0.70, versus the consensus of $0.67. Vascular Solutions, Inc. sees FY2013 revenue of $107-110 million, versus the consensus of $107.7 million.
""Vascular Solutions reported another very strong quarter, with continued double-digit sales growth to a new record quarterly level combined with ongoing improvement in our operating margin," said Howard Root, Chief Executive Officer of Vascular Solutions. "We are especially pleased to achieve growth in all three of our product categories in light of the continuing challenges in the global healthcare environment. Our consistently strong financial performance reflects our demonstrated ability to develop and launch clinically-relevant new products on a continuing basis. With approximately ten new products scheduled for launch this year and 40 total new product ideas in our pipeline, we remain optimistic about our continued revenue and earnings growth for 2013 and beyond."
For earnings history and earnings-related data on Vascular Solutions, Inc. (VASC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
- First Foundation (FFWM) Tops Q1 EPS by 1c
- Hess Corp. (HES) Tops Q1 EPS by 144c
Create E-mail Alert Related Categories
Earnings, Guidance, Management ChangesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
